Prediction and Analysis of SARS-CoV-2-Targeting &lt;i&gt;microRNA&lt;/i&gt; in Human Lung Epithelium

Chow, Jonathan Tak-Sum; Salmena, Leonardo

doi:10.20944/preprints202008.0253.v1

Cited by 23 publications

(3 citation statements)

References 42 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reproduced with permission [29] of the respiratory epithelium to infection. On the other hand, enhancing the expression levels of host miRNAs may provide protection against viral infection and replication [26].…”

Section: Indirect Effects Of Mirnas On Sars-cov-2 Infectionmentioning

confidence: 99%

“…Decrease [26] hsa-miR-155-3p and hsa-miR-139-5p They may provide cellular protection against viral infection and replication.…”

Section: Strategies For Designing Mirna Mimics and Antagonistsmentioning

confidence: 99%

“…Increase [26] miR-34a-3p and miR-495-5p They enhance X-box binding protein transcription factor and binding immunoglobulin protein expression by increasing the endoplasmic reticulum folding capacity and cell survival, respectively.…”

Section: Strategies For Designing Mirna Mimics and Antagonistsmentioning

confidence: 99%

See 2 more Smart Citations

The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection

Stojanović²,

Yasamineh

et al. 2021

Arch Virol

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there is no effective therapeutic approach for treating SARS-CoV-2 infections. MicroRNAs (miRNAs) have been recognized to target the viral genome directly or indirectly, thereby inhibiting viral replication. Several studies have demonstrated that host miRNAs target different sites in SARS-CoV-2 RNA and constrain the production of essential viral proteins. Furthermore, miRNAs have lower toxicity, are more immunogenic, and are more diverse than protein-based and even plasmid-DNA-based therapeutic agents. In this review, we emphasize the role of miRNAs in viral infection and their potential use as therapeutic agents against COVID-19 disease. The potential of novel miRNA delivery strategies, especially EDV™ nanocells, for targeting lung tissue for treatment of SARS-CoV-2 infection is also discussed.

show abstract

Section: Indirect Effects Of Mirnas On Sars-cov-2 Infectionmentioning

confidence: 99%

“…Decrease [26] hsa-miR-155-3p and hsa-miR-139-5p They may provide cellular protection against viral infection and replication.…”

Section: Strategies For Designing Mirna Mimics and Antagonistsmentioning

confidence: 99%

See 1 more Smart Citation

The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection

Stojanović²,

Yasamineh

et al. 2021

Arch Virol

View full text Add to dashboard Cite

show abstract

Suppression of miR-155 attenuates lung cytokine storm induced by SARS-CoV-2 infection in human ACE2-transgenic mice

Soni

Cabrera-Luque²,

Kar

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a recent global pandemic. It is a deadly human viral disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with a high rate of infection, morbidity and mortality. Therefore, there is a great urgency to develop new therapies to control, treat and prevent this disease. Endogenous microRNAs (miRNAs, miRs) of the viral host are key molecules in preventing viral entry and replication, and building an antiviral cellular defense. Here, we have analyzed the role of miR-155, one of the most powerful drivers of host antiviral responses including immune and inflammatory responses, in the pathogenicity of SARS-CoV-2 infection. Subsequently, we have analyzed the potency of anti-miR-155 therapy in a COVID-19 mouse model (mice transgenic for human angiotensin I-converting enzyme 2 receptor (tg-mice hACE2)). We report for the first time that miR-155 expression is elevated in COVID-19 patients. Further, our data indicate that the viral load as well as miR-155 levels are higher in male relative to female patients. Moreover, we find that the delivery of anti-miR-155 to SARS-CoV-2-infected tg-mice hACE2 effectively suppresses miR-155 expression, and leads to improved survival and clinical scores. Importantly, anti-miR-155-treated tg-mice hACE2 infected with SARS-CoV-2 not only exhibit reduced levels of pro-inflammatory cytokines, but also have increased anti-viral and anti-inflammatory cytokine responses in the lungs. Thus, our study suggests anti-miR-155 as a novel therapy for mitigating the lung cytokine storm induced by SARS-CoV-2 infection.

show abstract

The SARS-CoV-2 protein NSP2 impairs the microRNA-induced silencing capacity of human cells

Zou

Moch

Graille

et al. 2022

Preprint

View full text Add to dashboard Cite

The coronavirus SARS-CoV-2 is the cause of the ongoing pandemic of COVID-19. Given the absence of effective treatments against SARS-CoV-2, there is an urgent need for a molecular understanding of how the virus influences the machineries of the host cell. The SARS-CoV-2 generates 16 Non-Structural Proteins (NSPs) through proteolytic cleavage of a large precursor protein. In the present study, we focused our attention on the SARS-CoV-2 protein NSP2, whose role in the viral pathogenicity is poorly understood. Recent proteomic studies shed light on the capacity of NSP2 to bind the 4EHP-GIGYF2 complex, a key factor involved in microRNA-mediated silencing of gene expression in human cells. In order to gain a better understanding of the function of NSP2, we attempted to identify the molecular basis of its interaction with 4EHP-GIGYF2. Our data demonstrate that NSP2 physically associates with the endogenous 4EHP-GIGYF2 complex in the cytoplasm. Using co-immunoprecipitation and in vitro interaction assays, we identified both 4EHP and a central segment in GIGYF2 as binding sites for NSP2. We also provide functional evidence that NSP2 impairs the function of GIGYF2 in mediating mRNA silencing using reporter-based assays, thus leading to a reduced activity of microRNAs. Altogether, these data reveal the profound impact of NSP2 on the post-transcriptional silencing of gene expression in human cells, pointing out 4EHP-GIGYF2 targeting as a possible strategy of SARS-CoV-2 to take over the silencing machinery and to suppress host defenses.

show abstract

Prediction and Analysis of SARS-CoV-2-Targeting <i>microRNA</i> in Human Lung Epithelium

Cited by 23 publications

References 42 publications

The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection

The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection

Suppression of miR-155 attenuates lung cytokine storm induced by SARS-CoV-2 infection in human ACE2-transgenic mice

The SARS-CoV-2 protein NSP2 impairs the microRNA-induced silencing capacity of human cells

Contact Info

Product

Resources

About